Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility.

Authors: Esfandyari, Sahar; Chugh, Rishi Man; Park, Hang-Soo; Hobeika, Elie; Ulin, Mara; Al-Hendy, Ayman

Published In Cells, (2020 10 08)

Abstract: Female infertility is a global medical condition that can be caused by various disorders of the reproductive system, including premature ovarian failure (POF), polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and preeclampsia. It affects the quality of life of both patients and couples. Mesenchymal stem cells (MSCs) have received increasing attention as a potential cell-based therapy, with several advantages over other cell sources, including greater abundance, fewer ethical considerations, and high capacity for self-renewal and differentiation. Clinical researchers have examined the therapeutic use of MSCs in female infertility. In this review, we discuss recent studies on the use of MSCs in various reproductive disorders that lead to infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs in controlling MSC gene expression and driving MSC therapeutic outcomes. The clinical application of MSCs holds great promise for the treatment of infertility or ovarian insufficiency, and to improve reproductive health for a significant number of women worldwide.

PubMed ID: 33050021 Exiting the NIEHS site

MeSH Terms: Exosome Multienzyme Ribonuclease Complex/metabolism; Female; Humans; Infertility, Female/metabolism; Infertility, Female/therapy*; Mesenchymal Stem Cell Transplantation/methods*; Mesenchymal Stem Cell Transplantation/trends; Mesenchymal Stem Cells/metabolism*; MicroRNAs/metabolism; Ovarian Follicle; Primary Ovarian Insufficiency/metabolism; Primary Ovarian Insufficiency/therapy

Back
to Top